Cargando…

Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas

Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: FRANCESCHI, Joséphine, EHRET, Marine, VISSEAUX, Laetitia, DURLACH, Anne, BARBE, Coralie, DUROT, Éric, GRANGE, Florent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558323/
https://www.ncbi.nlm.nih.gov/pubmed/35083494
http://dx.doi.org/10.2340/actadv.v102.1087
_version_ 1784807416101076992
author FRANCESCHI, Joséphine
EHRET, Marine
VISSEAUX, Laetitia
DURLACH, Anne
BARBE, Coralie
DUROT, Éric
GRANGE, Florent
author_facet FRANCESCHI, Joséphine
EHRET, Marine
VISSEAUX, Laetitia
DURLACH, Anne
BARBE, Coralie
DUROT, Éric
GRANGE, Florent
author_sort FRANCESCHI, Joséphine
collection PubMed
description Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (n = 48), Sézary syndrome (n = 28) or aggressive non-mycosis fungoides/Sézary syndrome subtypes (n = 9). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides/Sézary syndrome identified age ≥ 70 years, Eastern Cooperative Oncology Group Performance Status ≥ 2, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides/Sézary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16–101 months.
format Online
Article
Text
id pubmed-9558323
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Society for Publication of Acta Dermato-Venereologica
record_format MEDLINE/PubMed
spelling pubmed-95583232022-10-20 Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas FRANCESCHI, Joséphine EHRET, Marine VISSEAUX, Laetitia DURLACH, Anne BARBE, Coralie DUROT, Éric GRANGE, Florent Acta Derm Venereol Original Article Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8+ T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (n = 48), Sézary syndrome (n = 28) or aggressive non-mycosis fungoides/Sézary syndrome subtypes (n = 9). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides/Sézary syndrome identified age ≥ 70 years, Eastern Cooperative Oncology Group Performance Status ≥ 2, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides/Sézary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16–101 months. Society for Publication of Acta Dermato-Venereologica 2022-03-22 /pmc/articles/PMC9558323/ /pubmed/35083494 http://dx.doi.org/10.2340/actadv.v102.1087 Text en © 2022 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license
spellingShingle Original Article
FRANCESCHI, Joséphine
EHRET, Marine
VISSEAUX, Laetitia
DURLACH, Anne
BARBE, Coralie
DUROT, Éric
GRANGE, Florent
Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
title Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
title_full Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
title_fullStr Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
title_full_unstemmed Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
title_short Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
title_sort survival and prognostic factors in patients with aggressive cutaneous t-cell lymphomas
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558323/
https://www.ncbi.nlm.nih.gov/pubmed/35083494
http://dx.doi.org/10.2340/actadv.v102.1087
work_keys_str_mv AT franceschijosephine survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas
AT ehretmarine survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas
AT visseauxlaetitia survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas
AT durlachanne survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas
AT barbecoralie survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas
AT duroteric survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas
AT grangeflorent survivalandprognosticfactorsinpatientswithaggressivecutaneoustcelllymphomas